

Carola Berking

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7290639/publications.pdf>

Version: 2024-02-01

202
papers

11,227
citations

41344

49
h-index

34986

98
g-index

231
all docs

231
docs citations

231
times ranked

16795
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1116-1119.	1.2	11
2	Clinical determinants of long-term survival in metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1467-1477.	4.2	10
3	A disease network-based deep learning approach for characterizing melanoma. <i>International Journal of Cancer</i> , 2022, 150, 1029-1044.	5.1	16
4	HDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 849.	4.1	5
5	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. <i>Cancers</i> , 2022, 14, 518.	3.7	6
6	A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKK β -Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 785231.	4.8	9
7	Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 783-790.	5.6	9
8	Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis. <i>JMIR Cancer</i> , 2022, 8, e29581.	2.4	14
9	Tebentafusp als neuartige Immuntherapie zeigt einen Überlebensvorteil beim metastasierten Uveamelanom und wird bereits in Deutschland eingesetzt. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 381-383.	0.8	0
10	Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials. <i>Scientific Reports</i> , 2022, 12, 5884.	3.3	6
11	Explainable artificial intelligence in skin cancer recognition: A systematic review. <i>European Journal of Cancer</i> , 2022, 167, 54-69.	2.8	42
12	Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2149-2158.e10.	0.7	7
13	Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement. <i>Current Oncology</i> , 2022, 29, 2909-2919.	2.2	5
14	Efficacy of Therapies for Actinic Keratosis Reply. <i>JAMA Dermatology</i> , 2022, , .	4.1	0
15	Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2022, 170, 42-53.	2.8	4
16	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
17	The need for regular training in skin cancer screening: a cross-sectional study among general practitioners in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	0
18	Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 345-354.e8.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 641-649.	2.4	9
20	Monitoring skin metastases during immunotherapy and targeted therapy using total body 3D photography. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e61-e63.	2.4	3
21	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. European Journal of Cancer, 2021, 143, 43-45.	2.8	1
22	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	2.5	2
23	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
24	Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey. Patient Preference and Adherence, 2021, Volume 15, 41-48.	1.8	0
25	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 608-610.	0.8	3
26	A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis. Current Oncology, 2021, 28, 950-960.	2.2	5
27	The Value of Total Body Photography for the Early Detection of Melanoma: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 1726.	2.6	28
28	Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 193-197.	2.4	5
29	One set to collect them all? The development of a core domain set for medium-to-giant congenital melanocytic naevi. British Journal of Dermatology, 2021, 185, 247-248.	1.5	0
30	Safety of topical interventions for the treatment of actinic keratosis. Expert Opinion on Drug Safety, 2021, 20, 801-814.	2.4	9
31	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	2.8	40
32	Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients. Journal of Immunotherapy, 2021, 44, 239-241.	2.4	2
33	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	2.8	10
34	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
35	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	2.8	15
36	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1678-1685.	2.4	10

#	ARTICLE	IF	CITATIONS
37	How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5761.	4.1	19
38	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1312-1316.	0.9	154
39	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , 2021, 13, 3359.	3.7	18
40	Onkologische Systemtherapie bis zum bitteren Ende?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1259-1260.	0.8	0
41	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. <i>JAMA Dermatology</i> , 2021, 157, 1066.	4.1	24
42	Another step on the road towards standardized outcome reporting for congenital melanocytic naevi: one more to go!. <i>British Journal of Dermatology</i> , 2021, 185, 881-882.	1.5	0
43	A Chimeric IL-15/IL-15R α Molecule Expressed on NF κ B-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10227.	4.1	5
44	A benchmark for neural network robustness in skin cancer classification. <i>European Journal of Cancer</i> , 2021, 155, 191-199.	2.8	34
45	Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy. <i>ESMO Open</i> , 2021, 6, 100248.	4.5	10
46	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. <i>European Journal of Cancer</i> , 2021, 156, 202-216.	2.8	115
47	c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. <i>European Journal of Cancer</i> , 2021, 157, 348-357.	2.8	17
48	Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion. <i>Journal of Immunotherapy</i> , 2021, 44, 71-75.	2.4	3
49	30 Years German Dermatologic Cooperative Oncology Group (DeCOG). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1682-1697.	0.8	0
50	30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1682-1697.	0.8	0
51	How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results. <i>Journal of Clinical Medicine</i> , 2021, 10, 4736.	2.4	5
52	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	2.8	10
53	Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. <i>Journal of Immunotherapy</i> , 2021, 44, 114-117.	2.4	5
54	BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11951.	4.1	8

#	ARTICLE	IF	CITATIONS
55	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. <i>BMJ Open</i> , 2021, 11, e049208.	1.9	9
56	Increasing Participation Rates in Germany's Skin Cancer Screening Program (HELIOS): Protocol for a Mixed Methods Study. <i>JMIR Research Protocols</i> , 2021, 10, e31860.	1.0	2
57	The more the better? An appraisal of combination therapies for actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 727-732.	2.4	18
58	Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020, 36, 126-134.	1.5	6
59	Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 515-519.	1.2	10
60	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2253.	2.4	11
61	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. <i>Nature Communications</i> , 2020, 11, 3774.	12.8	78
62	Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2516.	3.7	18
63	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9300.	4.1	23
64	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2020, 395, 1558-1568.	13.7	188
65	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
66	The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments. <i>Cancers</i> , 2020, 12, 1613.	3.7	11
67	Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors. <i>Facial Plastic Surgery</i> , 2020, 36, 249-254.	0.9	3
68	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality of care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 275-294.	0.8	57
69	The value of convolutional neural networks in the diagnosis of melanoma simulators. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1134-1135.	2.4	0
70	Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of the existing evidence. <i>British Journal of Dermatology</i> , 2020, 183, 380-382.	1.5	5
71	Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1079-1088.	2.5	15
72	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2020, 21, 294-305.	10.7	304

#	ARTICLE	IF	CITATIONS
73	Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis. <i>British Journal of Dermatology</i> , 2020, 183, 612-612.	1.5	1
74	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 400-413.	0.8	39
75	German YouTube™ videos as a source of information on cutaneous melanoma: a critical appraisal. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e642-e644.	2.4	9
76	Implications of the COVID-19 Pandemic for the Development and Update of Clinical Practice Guidelines: Viewpoint. <i>Journal of Medical Internet Research</i> , 2020, 22, e20064.	4.3	3
77	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	4.1	57
78	The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology. <i>European Journal of Dermatology</i> , 2020, 30, 757-758.	0.6	2
79	Patient Perception of Mobile Phone Apps for the Care and Prevention of Sexually Transmitted Diseases: Cross-Sectional Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16517.	3.7	5
80	Unmet information needs of patients with melanoma in Germany. <i>Melanoma Research</i> , 2019, 29, 196-204.	1.2	14
81	Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients. <i>Journal of Cancer Education</i> , 2019, 34, 760-767.	1.3	14
82	Deep neural networks are superior to dermatologists in melanoma image classification. <i>European Journal of Cancer</i> , 2019, 119, 11-17.	2.8	212
83	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. <i>European Journal of Cancer</i> , 2019, 119, 57-65.	2.8	134
84	Photodynamic therapy – to go™ – a strengths, weaknesses, opportunities and threats analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e447-e449.	2.4	0
85	Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. <i>Trials</i> , 2019, 20, 589.	1.6	3
86	Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2019, 8, 237.	5.3	6
87	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
88	Superior skin cancer classification by the combination of human and artificial intelligence. <i>European Journal of Cancer</i> , 2019, 120, 114-121.	2.8	197
89	Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 863-873.	2.4	26
90	Pathologist-level classification of histopathological melanoma images with deep neural networks. <i>European Journal of Cancer</i> , 2019, 115, 79-83.	2.8	156

#	ARTICLE	IF	CITATIONS
91	Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: reply from the authors. <i>British Journal of Dermatology</i> , 2019, 181, 424-425.	1.5	0
92	Patient Attitude towards Videodermoscopy for the Detection of Skin Cancer: A Cross-Sectional Study. <i>Oncology Research and Treatment</i> , 2019, 42, 319-325.	1.2	5
93	Noninvasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques. <i>Journal of Biophotonics</i> , 2019, 12, e201800391.	2.3	15
94	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , 2019, 111, 148-154.	2.8	197
95	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , 2019, 113, 47-54.	2.8	300
96	Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 652-654.	0.8	4
97	Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. <i>European Journal of Cancer</i> , 2019, 111, 30-37.	2.8	104
98	Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 947-956.	1.2	38
99	Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma – a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 25-32.	2.4	14
100	Local interventions for actinic keratosis in organ transplant recipients: a systematic review. <i>British Journal of Dermatology</i> , 2019, 180, 43-50.	1.5	35
101	Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2019, 180, 740-748.	1.5	25
102	The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 424-434.	3.3	22
103	BILATERAL VISUAL FIELD DEFECTS IN A PATIENT TREATED WITH THE MEK AND BRAF INHIBITORS TRAMETINIB AND DABRAFENIB FOR MELANOMA OF UNKNOWN ORIGIN. <i>Retinal Cases and Brief Reports</i> , 2019, 13, 215-219.	0.6	9
104	Patient Attitudes and Their Awareness Towards Skin Cancer-Related Apps: Cross-Sectional Survey. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13844.	3.7	19
105	Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 616-626.	0.9	15
106	Successful Treatment of Genital Warts with Ingenol Mebutate Monitored with Optical Coherence Tomography and Reflectance Confocal Microscopy. <i>Annals of Dermatology</i> , 2019, 31, 434.	0.9	4
107	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. <i>British Journal of Cancer</i> , 2018, 118, 785-792.	6.4	34
108	Indications and Use of Isotretinoin in Facial Plastic Surgery. <i>Facial Plastic Surgery</i> , 2018, 34, 075-081.	0.9	14

#	ARTICLE	IF	CITATIONS
109	MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. <i>Journal of Investigative Dermatology</i> , 2018, 138, 141-149.	0.7	29
110	Immunofluorescence and confocal microscopy for ex vivo diagnosis of melanocytic and non-melanocytic skin tumors: A pilot study. <i>Journal of Biophotonics</i> , 2018, 11, e201700211.	2.3	26
111	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018, 36, 1232-1239.	1.6	207
112	Targeted Therapy of Melanoma. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S86.	0.8	0
113	A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky032.	2.9	23
114	Melanoma. <i>Lancet</i> , The, 2018, 392, 971-984.	13.7	1,016
115	How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. <i>European Journal of Cancer</i> , 2018, 103, 41-51.	2.8	50
116	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018, 98, 10-16.	2.8	57
117	Information seeking and use of information resources among melanoma patients of German skin cancer centers. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1093-1101.	0.8	13
118	Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment. <i>Medical Oncology</i> , 2018, 35, 135.	2.5	14
119	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. <i>Journal of Clinical Oncology</i> , 2018, 36, 9501-9501.	1.6	16
120	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. <i>Journal of Clinical Oncology</i> , 2018, 36, 9527-9527.	1.6	25
121	The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. <i>Oncotarget</i> , 2018, 9, 34336-34346.	1.8	31
122	Facial-Aging Mobile Apps for Smoking Prevention in Secondary Schools in Brazil: Appearance-Focused Interventional Study. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e10234.	2.6	3
123	Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis. <i>JMIR Cancer</i> , 2018, 4, e10676.	2.4	17
124	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. <i>Journal of Medical Internet Research</i> , 2018, 20, e10976.	4.3	19
125	Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. <i>Journal of Medical Internet Research</i> , 2018, 20, e11871.	4.3	44
126	Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , 2018, 20, e11936.	4.3	277

#	ARTICLE	IF	CITATIONS
127	Optical coherence tomography imaging of basal cell carcinoma undergoing photodynamic therapy: A pilot study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 18, 133-137.	2.6	13
128	The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. <i>Oncogene</i> , 2017, 36, 5110-5121.	5.9	59
129	Low baseline levels of <sc>NK</sc> cells may predict a positive response to ipilimumab in melanoma therapy. <i>Experimental Dermatology</i> , 2017, 26, 622-629.	2.9	19
130	Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1377-1378.	4.2	3
131	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , 2017, 82, 56-65.	2.8	162
132	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , 2017, 81, 36-44.	2.8	76
133	Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. <i>Annals of Oncology</i> , 2017, 28, 3104-3106.	1.2	53
134	Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 60, 44-52.	7.7	90
135	UVâ€ŠschutzbÃ¼ndnis verabschiedet ein neues Grundsatzpapier zur VerhÃ¼ltnisprÃ¼vention: Vorbeugung gesundheitlicher SchÃ¼den der Sonne â€œ VerhÃ¼ltnisprÃ¼vention in der Stadt und auf dem Land. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 687-687.	0.8	0
136	Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. <i>BMC Cancer</i> , 2017, 17, 536.	2.6	113
137	Validation, in silico and in vitro, of a gene-signature based risk score in cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9560-9560.	1.6	2
138	NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21035-e21035.	1.6	1
139	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	7.0	480
140	Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 757-767.	10.7	562
141	A randomized, double-blind, phase <sc>III</sc>, multicentre study to evaluate the safety and efficacy of <sc>BF</sc> â€200 <sc>ALA</sc> (Ameluz ^{Â®}) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the <sc>BF</sc> â€Rhodo <sc>LED</sc> ^{Â®} lamp. <i>British Journal of Dermatology</i> , 2016, 175, 686-705.	1.5	74
142	Morphologic features of basal cell carcinoma using the enâ€face mode in frequency domain optical coherence tomography. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1919-1925.	2.4	17
143	A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2475-2484.	0.7	9
144	CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis. <i>Annals of Neurology</i> , 2016, 80, 294-300.	5.3	94

#	ARTICLE	IF	CITATIONS
145	Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside. <i>Experimental Dermatology</i> , 2016, 25, 831-838.	2.9	37
146	Kinetics of human myeloid-derived suppressor cells after blood draw. <i>Journal of Translational Medicine</i> , 2016, 14, 2.	4.4	34
147	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 951-959.	4.2	62
148	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	7.7	354
149	Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9558-9558.	1.6	0
150	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351.	4.4	56
151	Transient memory impairment and transient global amnesia induced by photodynamic therapy. <i>British Journal of Dermatology</i> , 2015, 173, 1258-1262.	1.5	11
152	Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1797-1806.	2.4	55
153	Daylight PDT with MAL — current data and practical recommendations of an expert panel. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1240-1249.	0.8	21
154	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
155	High-definition optical coherence tomography of melanocytic skin lesions. <i>Journal of Biophotonics</i> , 2015, 8, 681-686.	2.3	46
156	The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. <i>British Journal of Dermatology</i> , 2015, 173, 428-435.	1.5	138
157	Combination therapy of melanoma using kinase inhibitors. <i>Current Opinion in Oncology</i> , 2015, 27, 134-140.	2.4	18
158	Subluminescence photodynamic therapy of recalcitrant foot warts. <i>British Journal of Dermatology</i> , 2015, 172, 813-816.	1.5	7
159	In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins. <i>Cell Death and Disease</i> , 2015, 6, e1996-e1996.	6.3	20
160	Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. <i>British Journal of Dermatology</i> , 2015, 172, 816-818.	1.5	29
161	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA9002-LBA9002.	1.6	3
162	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA9002-LBA9002.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Allele frequencies of BRAF<i>V600</i> mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 37895-37905.	1.8	26
164	Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naïve advanced metastatic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20080-e20080.	1.6	0
165	Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11061-11061.	1.6	0
166	Basal Cell Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2014, 111, 389-95.	0.9	64
167	SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2212-2220.	0.7	70
168	Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. <i>Annals of Oncology</i> , 2014, 25, 747-753.	1.2	47
169	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. <i>Cancer Discovery</i> , 2014, 4, 94-109.	9.4	782
170	POU transcription factors in melanocytes and melanoma. <i>European Journal of Cell Biology</i> , 2014, 93, 55-60.	3.6	19
171	A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. <i>European Journal of Dermatology</i> , 2014, 24, 335-341.	0.6	12
172	Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: Pseudocysts as a sign of tumor regression. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 725-730.	1.2	47
173	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9031-9031.	1.6	2
174	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)â€™Decog-trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9071-9071.	1.6	1
175	Morphology of basal cell carcinoma in high definition optical coherence tomography: enâ€™face and slice imaging mode, and comparison with histology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e97-104.	2.4	71
176	A nine-gene signature predicting clinical outcome in cutaneous melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 249-258.	2.5	77
177	Actinic keratosis in the<i>en-face</i> and slice imaging mode of high-definition optical coherence tomography and comparison with histology. <i>British Journal of Dermatology</i> , 2013, 168, 120-128.	1.5	48
178	Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 581-587.	1.2	45
179	Cytodiagnosis of erosive melanoma and basal cell carcinoma of the skin using cutaneous tissue smear. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 251-261.	1.3	2
180	The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. <i>EMBO Molecular Medicine</i> , 2013, 5, 919-934.	6.9	31

#	ARTICLE	IF	CITATIONS
181	The genetic landscape of clinical resistance to RAF inhibition in melanoma.. Journal of Clinical Oncology, 2013, 31, 11009-11009.	1.6	1
182	Open-label, multicenter safety study of vemurafenib in patients with <i>BRAF^{V600}</i> mutationâ€“positive metastatic melanoma.. Journal of Clinical Oncology, 2013, 31, 9046-9046.	1.6	3
183	Risk factors for early-onset basal cell carcinoma in a German institution. European Journal of Dermatology, 2011, 21, 705-709.	0.6	25
184	Neue Entwicklungen in der Fluoreszenzdiagnostik. JDDG - Journal of the German Society of Dermatology, 2011, 9, 368-373.	0.8	1
185	Sorafenib and pegylated interferon-Î±2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology, 2011, 22, 1667-1674.	1.2	27
186	Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Experimental Dermatology, 2010, 19, e89-94.	2.9	56
187	Photodynamic Therapy of Necrobiosis Lipoidica â€“ A Multicenter Study of 18 Patients. Dermatology, 2009, 218, 136-139.	2.1	55
188	SOX9 and SOX10 but Not BRN2 Are Required for Nestin Expression in Human Melanoma Cells. Journal of Investigative Dermatology, 2009, 129, 945-953.	0.7	43
189	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonâ€“independent apoptosis in human melanoma cells. Journal of Clinical Investigation, 2009, 119, 2399-411.	8.2	322
190	Aktuelles zur photodynamischen Therapie und Fluoreszenzdiagnostik. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 565-581.	0.0	0
191	5â€²-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353
192	Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 722-728.	2.4	29
193	Photodynamic Therapy for Granuloma Annulare: More than a Shot in the Dark. Dermatology, 2008, 217, 329-332.	2.1	27
194	Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53. Cell Death and Differentiation, 2007, 14, 818-829.	11.2	40
195	The Efficacy of Photodynamic Therapy in Actinic Cheilitis of the Lower Lip: A Prospective Study of 15 Patients. Dermatologic Surgery, 2007, 33, 825-830.	0.8	77
196	Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFRâ€“1, câ€“kit) in nevi and melanoma. Journal of Cutaneous Pathology, 2007, 34, 7-14.	1.3	52
197	Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. British Journal of Dermatology, 2005, 153, 733-739.	1.5	75
198	Induction of Melanoma Phenotypes in Human Skin by Growth Factors and Ultraviolet B. Cancer Research, 2004, 64, 807-811.	0.9	82

#	ARTICLE	IF	CITATIONS
199	Photocarcinogenesis in human adult skin grafts. <i>Carcinogenesis</i> , 2002, 23, 181-187.	2.8	63
200	Basic Fibroblast Growth Factor and Ultraviolet B Transform Melanocytes in Human Skin. <i>American Journal of Pathology</i> , 2001, 158, 943-953.	3.8	72
201	Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. <i>Melanoma Research</i> , 2000, 10, 303-312.	1.2	90
202	Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminoimmunometric assay for S-100. <i>Archives of Dermatological Research</i> , 1999, 291, 479-484.	1.9	35